NexMed reports net loss for second quarter

October 1999
Biotech Financial Reports;Oct99, p4
Trade Publication
Reports on Robbinsville, New Jersey-based NexMed Inc.'s announcement of its revenue for the quarter ended June 30, 1999. Total net loss; Total sale from its joint venture operations in China; Information on the company.


Related Articles

  • NexMed Completes Study on Topical Impotence Treatment.  // Worldwide Biotech;Oct99, Vol. 11 Issue 10, p1 

    Reports on the announcement of NexMed Inc. on the evaluation of its proprietary alprostadil cream for treating male erectile dysfunction (MED) in a multiple-use clinical study in China that involved patients afflicted with MED. Results of the clinical study; Comments from Doctor Y. Joseph Mo,...

  • NexMed garners Japanese patent.  // Medical Device Daily;6/28/2010, Vol. 14 Issue 123, p7 

    The article reports on the decision of Japan's Patent Office to approve NexMed's patent "Prostaglandin Composition for the Treatment of Male Erectile Dysfunction."

  • NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.  // Biotech Business;Sep2003, Vol. 16 Issue 9, p4 

    Reports the progress in the topical treatment for premature ejaculation development project of NexMed Inc., a developer of innovative transdermal treatments based on its NexACT proprietary drug delivery technology.

  • INVEST NEW JERSEY. McKnight, Marshall // Business News New Jersey;12/05/2000, Vol. 13 Issue 49, p16 

    Focuses on the increased stock prices of New Jersey-based NexMed Inc. Growth of stock value following the completion of the Phase III of the company's Befar erectile dysfunction cream.

  • Bio-Quant Successor Attracts $2.3M Investment. Chambers, Heather // San Diego Business Journal;2/15/2010, Vol. 31 Issue 7, p5 

    The article reports on the 2.3 million U.S. dollars promissory notes raised by NexMed Inc. from two investors in connection to its acquisition of San Diego-based Bio-Quant Inc.

  • Financings Roundup.  // BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3 

    The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed....

  • NexMed Shares Fall Hard as Novartis Nixes NDA. Hollingsworth, Catherine // BioWorld Today;8/28/2008, Vol. 19 Issue 168, p1 

    The article reports on a decline in the value of NexMed's shares by 81.6% after its partner, Novartis AG, decided not to file for a new drug application for a topical nail fungus product that uses NexMed's drug delivery technology. Such decision by Novartis was attributed to a negative Phase III...

  • FINANCINGS ROUNDUP.  // BioWorld Today;3/18/2010, Vol. 21 Issue 52, p8 

    This section offers news briefs on biotechnological companies. Biomoda Inc. has partnered with a syndicate of institutional investors for a placement of up to 2 million U.S. dollars with LifeTech Capital acting as the exclusive placement agent. NexMed Inc. produced 1.4 million U.S. dollars after...

  • New money breathes life into NexMed. Goldblatt // Business News New Jersey;10/11/99, Vol. 12 Issue 37, p10 

    Reports on Robbinsville, New Jersey-based NexMed's private placement of securities in October 1999. Amount raised from the placement; Background information about the company's lead product, Alprox-TD for male sexual dysfunction; Profile on Chief Executive Officer Y. Joseph Mo; Key to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics